Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical royalty/royalty-aggregator company. Completed its acquisition of XOMA Royalty Corp. on July 14, 2026 for $39/share ($739M total) plus contingent value rights tied to XOMA's litigation against Janssen Biotech. Distinct from candidate 'Merand Pharmaceuticals' (unrelated UVA-linked drug discovery company).